利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.031 秒)

    Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
    3.
    发明授权
    Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes 有权
    通过添加食管表位增强肿瘤相关抗原的免疫原性

    公开(公告)号：US08916169B2

    公开(公告)日：2014-12-23

    申请号：US13716566

    申请日：2012-12-17

    申请人： NewLink Genetics Corp.

    发明人： Mario R. Mautino ,  Nicholas N. Vahanian ,  Won-Bin Young ,  Gabriela Rossi ,  Charles J. Link ,  Firoz Jaipuri

    IPC分类号： A61K38/16 ,  A61K39/39 ,  C07H5/04 ,  A61K39/00

    CPC分类号： C07H5/04 ,  A61K31/70 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55511 ,  C07H15/00 ,  C07H15/04

    摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

    摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变​​以引入αGal表位或αGal糖模拟表位，以允许通过以下方式增强抗原的调理作用 天然抗αGal抗体刺激TAA捕获和表达，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。

    IDO inhibitors
    6.
    发明授权
    IDO inhibitors 有权

    公开(公告)号：US09850248B2

    公开(公告)日：2017-12-26

    申请号：US15181062

    申请日：2016-06-13

    申请人： NewLink Genetics Corporation

    发明人： Mario Mautino ,  Sanjeev Kumar ,  Jesse Waldo ,  Firoz Jaipuri ,  Tanay Kesharwani ,  Xiaoxia Zhang

    IPC分类号： C07F9/6561 ,  C07D487/04

    CPC分类号： C07D487/04 ,  C07F9/6561

    摘要： Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.

    Fused imidazole derivatives useful as IDO inhibitors
    7.
    发明授权
    Fused imidazole derivatives useful as IDO inhibitors 有权
    用作IDO抑制剂的熔融咪唑衍生物

    公开(公告)号：US09388191B2

    公开(公告)日：2016-07-12

    申请号：US14794193

    申请日：2015-07-08

    申请人： NewLink Genetics Corporation

    发明人： Mario Mautino ,  Sanjeev Kumar ,  Jesse Waldo ,  Firoz Jaipuri ,  Tanay Kesharwani ,  Xiaoxia Zhang

    IPC分类号： C07D487/04 ,  C07F9/6561

    CPC分类号： C07D487/04 ,  C07F9/6561

    摘要： Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.

    摘要翻译： 目前提供的是可用于调节吲哚胺2,3-双加氧酶活性的IDO抑制剂及其药物组合物; 治疗吲哚胺2,3-双加氧酶（IDO）介导的免疫抑制; 治疗受抑制吲哚胺-2,3-双加氧酶酶活性的医学病症; 提高抗癌治疗的有效性，包括施用抗癌剂; 治疗与癌症有关的肿瘤特异性免疫抑制; 并治疗与感染性疾病相关的免疫抑制。

    Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
    8.
    发明授权
    Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes 有权
    通过添加食管表位增强肿瘤相关抗原的免疫原性

    公开(公告)号：US09090643B2

    公开(公告)日：2015-07-28

    申请号：US13716569

    申请日：2012-12-17

    申请人： NewLink Genetics Corp.

    发明人： Mario R. Mautino ,  Nicholas N. Vahanian ,  Won-Bin Young ,  Gabriela Rossi ,  Charles J. Link ,  Firoz Jaipuri

    IPC分类号： A61K31/7012 ,  C07H5/04 ,  C07H15/04 ,  C07H15/00 ,  A61K39/00 ,  A61K39/39 ,  A61K31/70

    CPC分类号： C07H5/04 ,  A61K31/70 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55511 ,  C07H15/00 ,  C07H15/04

    摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

    摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变​​以引入αGal表位或αGal糖模拟表位，以允许通过以下方式增强抗原的调理作用 天然抗αGal抗体刺激TAA捕获和表达，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。

    ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES
    9.
    发明申请
    ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES 有权
    肿瘤相关抗体的增强免疫球蛋白增加ALPAGAL EPITOPES

    公开(公告)号：US20130164318A1

    公开(公告)日：2013-06-27

    申请号：US13716566

    申请日：2012-12-17

    申请人： NewLink Genetics Corp.

    发明人： Mario R. MAUTINO ,  Nicholas N. Vahanian ,  Won-Bin Young ,  Gabriela Rossi ,  Charles J. Link ,  Firoz Jaipuri

    IPC分类号： A61K39/00

    CPC分类号： C07H5/04 ,  A61K31/70 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/55511 ,  C07H15/00 ,  C07H15/04

    摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

    摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 本发明描述了基于纯化的TAA蛋白或TAA衍生的合成肽的预防或治疗性癌症疫苗，其通过化学，酶学或化学 - 酶学方法改变​​以引入αGal表位或αGalglycomimetic表位，以便通过以下方式增强抗原的调理作用 天然抗αGal抗体刺激TAA捕获和表达，从而诱导由肿瘤表达的TAA的体液和细胞免疫应答。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。